SRD5A3
Polyprenal reductase
As of the edition of 20 October 2026, SRD5A3 (polyprenal reductase, UniProt Q9H8P0) has 3 drugs tested at it and 5 companies on the list, 0 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9H8P0
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Disease areas
- Urinary and reproductive; Cancer; Pregnancy and women's health; Skin and connective tissue; Chemically induced; Digestive system; Hormones; Mental health
- Registered trials of its drugs
- 188
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Abiraterone | Marketed | Phase 4 | none listed |
| Dutasteride | Marketed | Phase 4 | none listed |
| DKF-313 | Active | Phase 3 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 3 |
| Engaged | 2 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| GSK | Route B |
| Waylis Therapeutics | Route B |
| Johnson & Johnson | Route B |
The other 2 companies at SRD5A3
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at SRD5A3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.